0001479290-24-000084.txt : 20240503 0001479290-24-000084.hdr.sgml : 20240503 20240503084247 ACCESSION NUMBER: 0001479290-24-000084 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240501 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Beraud Jill CENTRAL INDEX KEY: 0001520061 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 24910934 MAIL ADDRESS: STREET 1: C/O LEVI STRAUSS & CO. STREET 2: 1155 BATTERY STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wk-form4_1714740158.xml FORM 4 X0508 4 2024-05-01 0 0001479290 Revance Therapeutics, Inc. RVNC 0001520061 Beraud Jill C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 1 0 0 0 0 Common Stock 2024-05-01 4 A 0 15000 0 A 43606 D Stock Option (Right to buy) 3.795 2024-05-01 4 A 0 23458 0 A 2034-04-30 Common Stock 23458 23458 D Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 1, 2025 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to the Director's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. /s/ Dwight Moxie, Attorney-in-Fact 2024-05-03